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The impact of disabilities on quality of life in people
with multiple sclerosis
K Wynia1,2, B Middel1,3, JP van Dijk1, JHA De Keyser2 and SA Reijneveld1
Objective People with Multiple Sclerosis (MS) experience lower levels of quality of life (QOL) than peo-
ple from the general population. We examined the relative impact of MS-related disabilities on QOL.
Method Data were obtained from a sample of 530 patients who completed the Multiple Sclerosis
Impact Profile (MSIP), a disability measure based on the International Classification of Functioning,
Disabilities and Health (ICF) and two generic health-related QOL measures, the Medical Outcome
study Short Form Questionnaire (SF-36) and the World Health Organization Quality Of Life-BREF
(WHOQOL-BREF). The impact of disabilities on QOL was estimated using hierarchical multiple
regression analyses after controlling for the clinical course of MS.
Results Disabilities contributed to a unique and substantial extent to QOL variance. “Impairments
in mental functions” was the most important QOL predictor. “Fatigue” showed the highest preva-
lence and severity scores, while the impact on QOL was limited. The estimated impact on QOL
appeared to be dependent on the applied QOL measure: the WHOQOL-BREF was sensitive to dis-
abilities related to all four ICF components, while the SF-36 was only sensitive to disabilities belong-
ing to the ’body functions’ and ‘activities’ components.
Conclusion Treatment programmes should target impairments in cognitive functioning, emotional
functioning and sleep. Interventions are best evaluated using the WHOQOL-BREF. Multiple Sclerosis
2008; 14: 972–980. http://msj.sagepub.com
Key words: disability; international classification of functioning; disabilities and health; multiple
sclerosis; Multiple Sclerosis Impact Profile; quality of life
Introduction
Multiple sclerosis (MS) is a chronic, demyelinating,
neurodegenerative disorder of the central nervous
system (CNS). Its onset is usually in early adulthood
and the course of disease is often progressive and
debilitating [1]. Common symptoms include optic
nerve dysfunction (e.g., visual failure), sensory
disturbance (such as facial pain, sensory level distur-
bance, numbness, or tingling sensations), pyrami-
dal tract dysfunction (such as increased muscle
tone and hyperreflexia), ataxia (such as failure of
muscle control in limbs resulting in lack of balance
and co-ordination or disturbance of gait), double
vision, bladder and/or bowel dysfunction, and sex-
ual dysfunction [1]. In addition, fatigue, cognitive
impairment, and depression are often indicated as
relevant co-occurring symptoms in MS.
People with MS experience lower quality of life
(QoL) levels than people from the general popula-
tion in health-related QoL domains [2,3]. MS-
related disabilities are a likely explanation for this
poorer QoL. This has been reported for a number of
disabilities, such as fatigue [4–6], cognitive and emo-
tional functioning [7], depression [4,5,8,9], chronic
pain [10], and bladder and sexual dysfunction [11].
Although these studies generated clinically
important information, they are limited in that
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each study focused on the influence of only one or
two disabilities on QoL (univariate analysis). No evi-
dence is available on the relative impact of a num-
ber of MS-related disabilities on QoL (multivariate
analysis). This evidence could help to understand
the impact of MS, and not only of a specific dis-
ability, on QoL, which could in turn assist when
setting priorities in treatment programs focusing
on improvement of QoL with MS. Therefore, the
aim of this study is to examine the relative contri-
bution of all known MS-related disabilities on QoL.
We have used the international classification of
functioning, disabilities and health (ICF) definition
for disabilities: “disability is an umbrella term for
impairments in body functions and structures, lim-
itations in activities and restrictions in participa-
tion” [12]. We controlled for disease course when
analyzing the impact of disabilities on QoL. The
clinical course of MS can vary from stable, to slowly
progressive to rapidly progressive. It is known that
disease course can influence QoL, meaning that, all
other factors being equal, the more aggressive the
disease course, the lower the QoL [13,14].
Methods
Samples
We applied a postal survey to two samples of
patients withMS –members of theMS patients’ asso-
ciation in the North of the Netherlands (PA sample)
and patients from the Groningen MS center, part of
the Neurology Department of the University Hospi-
tal (UH sample). Respondents could not participate
in both samples. Of the 172 questionnaires sent out
in the PA sample, 153 questionnaires (89% response
rate) were returned and used for analyses. Of the
562 patients in the UH sample, 377 patients (67%
response rate) completed the questionnaires. The
non-responders in both samples did not differ in
age and gender from participating patients.
Measures
Multiple Sclerosis Impact Profile (MSIP)
We applied the MSIP to assess MS-related disabilities
[15,16]. The MSIP is a recently developed measure
with established psychometric properties and is
based on the International Classification of Func-
tioning, Disability and Health [12]. TheMSIP reflects
an objectified view of the prevalence and severity of
MS-related disabilities and consists of 36 items
divided over seven scales and has four additional
impairment items. Item scores are graded on three to
five-point rating scales with discrete responses, rang-
ing from 0 (no disability) to 3 or 4 (complete disabil-
ity). Scores are summed for each scale. MSIP scores
can vary from 0 to 12–24 for the scale variables, and
from 0 to 4 for the single impairment items [15]. For
reasons of comparability of the scores for each scale
and single impairment items, in this study the
summed and individual scores were multiplied to
obtain a result ranging from 0 to 100.
The MSIP showed satisfactory levels of internal
consistency. Cronbach’s alphas ranged between
0.49 (environmental factors) and 0.91, whereas the
mean inter-item correlations ranged between 0.19
(environmental factors) and 0.65. Test-retest reli-
ability intraclass correlations ranged between 0.65
(environmental factors) and 0.97.
QoL measures
QoL was assessed using two generic health-related
QoL measures, the SF-36 and the WHOQOL-BREF.
SF-36 consists of eight scales and two separate ques-
tions covering physical, psychological, and social
aspects of health [17]. Item scores were coded,
summed, and transformed to a scale ranging from
0 (worst health) to 100 (best health) for each
dimension. In a previous Dutch study of patients
with MS [18], the SF-36 showed satisfactory levels
of internal consistency. Cronbach’s alphas ranged
between 0.69 and 0.93, and test–retest reliability
correlation coefficients ranged between 0.48 and
0.87. In our study, Cronbach’s alphas ranged
between 0.74 and 0.96.
The WHOQOL-BREF [19] was the second QoL
measure applied in this study. The WHOQOL-
BREF consists of 26 items divided into four domains
covering physical, psychological, social, and envir-
onmental aspects and has two single-item ques-
tions. For each scale, item scores were coded,
summed, and transformed to a scale ranging from
0 (worst health) to 20 (best health). In a previous
Dutch study [20], the WHOQOL-BREF showed sat-
isfactory levels of internal consistency. Cronbach’s
alphas ranged between 0.66 and 0.80. In our study,
Cronbach’s alphas ranged between 0.63 and 0.81.
Disease course
The various clinical courses of MS can usually be
characterized either as episodic acute periods of
worsening, or gradually progressive deterioration
of neurological functioning, or as a combination
of the two [21]. To assess the course of the disease,
respondents were asked to choose a description for
the course of MS that best suited their case out of
five briefly described recognizable disease courses.
These descriptions were used to identify whether
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patients had experienced a stable (with or without
relapses), slowly progressive (with or without
relapses), or rapidly progressive disease course over
the preceding 6 months [13,22]. Because the disease
course subgroups are based on self-reports, they are
similar but not equal to distinctions in disease
course made by neurologists.
Procedures
Respondents in both samples completed the MSIP
[15], the WHOQOL-BREF [19], and demographic
and disease course questions. In addition, PA sam-
ple respondents also completed the SF-36 [17].
The local University Hospital Medical Ethics
Committee approved the research proposals for
both studies. Written informed consent from
respondents from both samples was obtained.
Analysis
Analysis of variance (ANOVA) for multiple compar-
isons with post-hoc Bonferroni correction was used
to determine statistically significant differences
between the disease course subgroups for the con-
tinuous variables. For the categorical variables, the
k-independent samples test was applied with post-
hoc analysis for Mann–Whitney U-tests.
Next, the impact of the MS-related disabilities on
QoL was assessed using a series of hierarchical
regression analyses with each of the QoL scale
variables as dependent variables. On the basis of sta-
tistically significant correlations of the most impor-
tant background variables (age, gender, marital sta-
tus, and educational level) with the QoL dependent
variables, age was included as the covariate for five
QoL variables and educational level as the covariate
for two QoL variables. Before entering variables into
the analysis, dummy variables were generated for the
categorical variables (disease course and educational
level) and for the four single impairment items
(fatigue, pain, impairment in speech functions, and
impairment in sight functions). Background and dis-
ease course variables were then entered in the regres-
sion model at the first step and the MSIP-disability
variables (all in one) at the second step to determine
whether they explained a significant percentage of
the variance in QoL. The expected direction of stan-
dardized β-weights is negative, meaning that less dis-
ability equated to better QoL.
Results
Samples
The characteristics of the PA and UH samples were
similar. More detailed information on the compari-
son of the PA and UH was reported earlier [15]. The
results for the whole sample are presented in
Table 1. The characteristics of the disease course
sub-samples were similar for most characteristics
but differed for employment status and age. As
Table 1 Characteristics of total sample and for sub-samples for course of MS





N (%) 530 (100) 235 (43) 243 (44) 26 (5)
Gendera
Female (%) 375 (71) 174 (74) 168 (69) 16 (62) 0.273
Male (%) 155 (29) 61 (26) 75 (31) 10 (39)
Ageb
Mean (SD) 50 (11) 47 (11) 53 (10) 51 (11) 0.000
Range 23–85 23–80 27–85 29 (72)
Marital status (%)a
Married/partnership 414 (80) 182 (78) 201 (83) 21 (81) 0.300
Unmarried/widowed/divorced 106 (20) 52 (22) 40 (17) 5 (19)
Educational level (highest level) (%)a
Primary or secondary school/vocational training 362 (70) 157 (68) 169 (70) 19 (73) 0.740
Higher professional education/university 157 (30) 75 (32) 71 (30) 7 (27)
Employment status (%) (more answers possible)a
Following a training or study program 19 (4) 13 (6) 5 (2) — 0.074
Full-time employment 45 (9) 34 (15) 9 (4) 1 (4) 0.000
Part-time employment 67 (13) 39 (17) 22 (9) 2 (8) 0.033
Part-time retired because of MS 65 (12) 36 (15) 22 (9) 4 (15) 0.101
Full-time retired because of MS 260 (50) 86 (37) 148 (61) 16 (62) 0.000
Housewife/househusband 164 (31) 74 (32) 77 (32) 7 (27) 0.882
Retired because of age 42 (8) 11 (5) 28 (12) 2 (8) 0.024
Years since MS Diagnosisb
Mean (SD) 13 (8) 12 (8) 13 (8) 11 (6) 0.098
Range 1–53 1–53 1–36 2–32
aANOVA analysis and bChi-square analysis for comparison of disease course sub-samples.
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expected, a larger proportion of respondents in the
stable group participated in employment when
compared with both samples with progressive MS.
Consequently, a larger proportion of respondents
with progressive disease course had retired because
of MS than respondents with stable MS. People with
stable MS were slightly younger than people with
progressive disease course.
Prevalence and severity of disabilities
The prevalence and mean severity scores for the
MS-related disabilities are shown in Table 2.
“Fatigue” was reported as the most severe disability
and was also the most prevalent. “Limitations in
activities of daily living” was the second most severe
disability followed by “limitations in basic move-
ment activities”, “impairments in muscle and move-
ment functions” and “impairments in excretion and
reproductive functions”.
As expected, disabilities differed statistically sig-
nificantly between the disease course subgroups,
except for lack of support in environmental factors.
Disabilities in patients with rapidly progressive MS
were more severe compared with the disabilities in
patients with slowly progressive MS, which in turn
were more severe than the disabilities in patients
with stable MS. Of note, post-hoc analyses were sig-
nificant for all comparisons between the stable and
progressive subgroups. However, only 4 of 11 com-
parisons between the slowly progressive and rapidly
progressive subgroups were significant, meaning
that the severity of disabilities were at about the
same level in both progressive subgroups except
for impairments in muscle and movement func-
tions, basic movement functions, fatigue, and
impairments in seeing functions.
Impact of disabilities on the SF-36 variables
Table 3 presents the results of the regression analysis
designed to explain the relative role of each disability
in the prediction of health-related QoL evaluated by
the eight SF-36 variables. The disability variables
contributed statistically relevantly to a unique seg-
ment of the variance for all SF-36 domains, especially
social functioning, mental health, and bodily pain.
Most standardized β-weights were in the
expected direction and showed that “impairments
in mental functions” was a significant predictor for
five of eight SF-36 domains, meaning that patients
who reported less impairment in mental functions
(cognitive, emotional, and sleep functions) reported
better QoL in the domains of mental health, emo-
tional functioning, social functioning, bodily pain,
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was an important predictor in social functioning,
mental health, and the physical function domains
of QoL, meaning that patients who were less lim-
ited reported better QoL. “Limitation in basic move-
ment activities” was a significant predictor in the
QoL domains for mental health and social function-
ing. However, on the contrary to expectations,
betas were positive here, meaning that patients
who were more limited in these activities (such as
maintaining or changing the body position, trans-
ferring oneself, or in the use of hand and arm)
reported better QoL. “Pain” was a significant predic-
tor for the physical functioning and bodily pain
QoL domains, with a beta in the expected direction.
Finally, “fatigue” was a statistically significant pre-
dictor of physical functioning, but showed a posi-
tive beta, meaning that a patient with more severe
fatigue complaints reported better QoL for this
domain.
Impact of disabilities on the WHOQOL-BREF
variables
The results of the regression analysis to determine
the effect of the various disabilities on health-
related QoL, evaluated by the four WHOQOL-BREF
domains, are presented in Table 4. The disability
variables contributed to a unique segment of the var-
iance for all four QoL domains. The standardized β-
weights were in the expected direction and showed
that “impairments in mental functions”was a signif-
icant predictor in all QoL domains and even the
most significant predictor in physical health and
psychological health, meaning that patients who
reported less impairment in mental functions
reported a better QoL. The second most important
predictor for three of four QoL variables was “lack
of support from environmental factors”, meaning
that patients who reported less lack of support from
immediate family, personal assistance or the social
security and health services reported better QoL in
the psychological health, social relationships, and
environment domains. “Restrictions in participation
in life situations” was the strongest predictor in the
environment QoL domain and the second strongest
predictor of psychological health, meaning that
patients with fewer restrictions in participation
reported better QoL. “Impairments in excretion and
reproductive functions” was the most causative pre-
dictor for the social relationships QoL domain.
Patients who reported more impairment in excre-
tion and reproductive functions reported a poorer
QoL. Furthermore, “limitations in activities of daily
living” and “pain” were statistically significant pre-
dictors of QoL for physical health.
Discussion
In this study we examined the relative impact of
various MS-related disabilities on health-related
QoL. Our findings show that “impairment in men-
tal functions” was the most important predictor of
health-related QoL. Fatigue was the most severe
impairment with the highest prevalence in all











Muscle and movement functions −0.17* 0.06 0.16 0.09
Excretion and reproductive functions 0.11 −0.07 −0.37** 0.10
Mental functions −0.38** −0.42** −0.18* −0.23*
Limitations in …
Basic movement activities −0.02 0.00 −0.11 −0.13
Activities of daily living −0.27* −0.00 0.07 −0.03
Restrictions in …
Participation in life situations −0.13 −0.21*** −0.09 −0.28***
Lack of support from …
Environmental factors −0.06 −0.17*** −0.23** −0.31**
Impairments
Fatigue −0.05 0.05 0.06 0.02
Pain −0.15* 0.04 −0.02 −0.03
Impairment in speech functions 0.03 0.00 0.05 0.10
Impairment in seeing functions 0.04 0.01 −0.03 −0.02
Adjusted R² 0.60 0.41 0.25 0.35
R² change 0.39 0.29 0.23 0.27
F 23.94** 13.51** 6.41** 9.16**
F change 20.14** 10.49** 6.28** 8.74**
In bold: statistically significant β values and R² change values.
*P < 0.05; **P < 0.001; ***P < 0.01.
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disease course subgroups, whereas the impact on
QoL was not statistically significant in any of the
QoL domains, except for physical functioning eval-
uated using the SF-36.
The results of regression analysis showed that the
contribution of disabilities differed for the compara-
ble domains in both QoL measures (i.e., mental
health in SF-36 and psychological health in
WHOQOL-BREF) indicating that both measures
operationalized these dimensions differently. In
general, QoL using the SF-36 was sensitive to the
MSIP “impairments in body functions” and the
“limitations in activities” disability variables,
whereas QoL measured by the WHOQOL-BREF
was also sensitive to the “restrictions in participa-
tion” and “lack of support of environmental factors”
variables. These differences between the QoL mea-
sures can be explained by the background of both
measures – the SF-36 originated in the early days of
QoL measurement development in which the focus
was on physical functioning, whereas the
WHOQOL-BREF is a more recently developed mea-
sure based on a broader and more balanced defini-
tion of QoL, which includes participation in life
situations and the influence of the environment.
Our findings of a very high prevalence and sever-
ity for fatigue confirmed findings in earlier studies
[23]. However, on the contrary to earlier findings,
fatigue in our study showed a limited impact on
QoL compared with other studies examining the
impact of fatigue on QoL [5,6]. An explanation
may be that the effect of fatigue on QoL is mediated
by the effect of other MS-related impairments on
QoL. Previous studies of the effect of single impair-
ments on QoL were unable to adjust for this medi-
ating effect.
Impairments in mental functions, including
impairments in cognitive, emotional, and sleep
functions, were reported by more than 80% of the
respondents in the total sample. Therefore, their
prevalence is far higher than findings in earlier
studies performed on cognitive impairments (40–
65%) [24,25] and depression (lifetime prevalence
of 50% and annual prevalence of 20%) [26]. A pos-
sible explanation could be the combination of both
aspects into one variable “mental functioning”.
Earlier findings that cognitive impairments have a
major impact on all aspects of QoL [24,25] were
confirmed in our study. The same holds true for
the impact of depression on QoL [4,5,8,9]. The
high prevalence of impairments in excretion and
reproductive functions found in earlier studies [27]
was confirmed in this study. Bowel and bladder dys-
functions were related to a reduced quality of social
functioning [11,28]. This is confirmed by our find-
ings – when QoL is evaluated using the WHOQOL-
BREF. Sexual disturbance was associated with a
reduced quality of mental health [11,29], which
could not be confirmed by our findings – “excretion
and reproductive functions” was the most impor-
tant explanatory aspect of QoL concerning social
relationships (WHOQOL-BREF), but showed no sta-
tistically significant contribution to mental health
(SF-36) or psychological health (WHOQOL-BREF).
The prevalence of pain in our sample matched
results in earlier studies [10,30]. These studies also
reported that pain is particularly correlated with the
mental health and physical functioning aspects of
QoL. In our study, pain was the most causative var-
iable in QoL related to physical functioning (SF-36),
physical health (WHOQOL-BREF), and bodily pain
(SF-36), but showed no significant contribution to
mental health (SF-36) or psychological health
(WHOQOL-BREF).
We found some statistically significantly positive
betas (i.e., more disability = better QoL) for the MSIP
“limitations in basic movement activities” in the SF-
36 social functioning and mental health variables,
and for “fatigue” in the SF-36 physical functioning
variable, where a negative beta was expected. A pos-
sible explanation could be the inter-item correlation
between the MSIP variables. As we entered the MSIP
variables at the same time (all in one) in the regres-
sion model (multivariate analysis), these correla-
tions could explain the positive betas as a case of
confounding correlations between the MSIP vari-
ables, meaning that effects of the separate disabil-
ities can be influenced by the effects of other MS-
related disabilities. We, therefore, applied the MSIP
variables with a positive beta as a single explaining
variable in the regression model (univariate analy-
sis). The direction in two of the three betas thereby
reversed to statistically not significant values, and
the direction of the third beta (the limitations in
basic movement activities for the social functioning
variable) changed to the expected negative direction
(see figures between brackets in Table 3). Another
explanation for these unexpected results can be
the finding that the impact on QoL appeared to be
dependent on the applied QoL measure. The
WHOQOL-BREF was sensitive to disabilities related
to all four ICF components, whereas the SF-36 was
only sensitive to disabilities in the body functions
and activities components and not for disabilities
in the participation and environmental factors com-
ponents. Interestingly, we only found positive betas
using the SF-36 as the outcome. Apparently, the
WHOQOL-BREF is better able to measure the effect
of each disability separately.
Methodological considerations
We succeeded in obtaining data from a representa-
tive sample of people with MS as regards the num-
ber of respondents, demographic variables, and
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disease-related variables (years from diagnosis and
disease course). The unusually high response rate
in the PA sample (89%) is probably because of the
fact that these respondents were participating in
another longitudinal study and we did not
approach non-responders or dropouts. Therefore,
we assume that at the time of our measurement,
patients in the PA sample were highly motivated
and willing to complete our questionnaires. Patient
characteristics from both PA and UH samples were
similar to what has already been published [15].
One issue that may limit the representativeness
of our findings is that the number of patients (5%)
who reported a rapidly progressive disease course
was limited. Although it is known that a minority
of patients (prevalence about 15%) have primary
progressive MS [31], this sub-sample was probably
less representative for patients with a primary pro-
gressive disease course.
Furthermore, there might have been some scal-
ing bias or systematic bias because of the use of
self-report questionnaires, but their effect on the
final results is probably neutralized through the
application of self-report questionnaires in the dis-
ability and the QoL evaluation.
Implications
This study generated new evidence on the relative
impact of various disabilities on health-related QoL.
As disabilities in mental functions turned out to
have the largest impact on QoL and also showed a
high prevalence among patients with MS (more
than 80%), professionals should be aware of this
finding. Further work is needed to explore whether
interventions with the intention to try and improve
cognitive functioning can improve QoL as well as
cognitive functioning. Furthermore, treatment pro-
grams should give priority to interventions con-
cerning impairments in emotional functioning
and sleep, as both aspects are relevant aspects of
mental functioning.
Their effects are best evaluated using the
WHOQOL-BREF because this measure seems more
sensitive to reflect the impact of disabilities on QoL.
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